AbbVie Inc. (ABBV)
| Market Cap | 242.80B |
| Revenue (ttm) | 56.74B |
| Net Income (ttm) | 7.59B |
| Shares Out | 1.76B |
| EPS (ttm) | 4.24 |
| PE Ratio | 32.42 |
| Forward PE | 14.39 |
| Dividend | $5.92 (4.30%) |
| Ex-Dividend Date | Apr 13, 2023 |
| Volume | 1,225,969 |
| Open | 137.00 |
| Previous Close | 136.87 |
| Day's Range | 136.94 - 138.31 |
| 52-Week Range | 131.10 - 168.11 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 164.94 (+19.88%) |
| Earnings Date | Jul 28, 2023 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with C... [Read more]
Financial Performance
In 2022, AbbVie's revenue was $58.05 billion, an increase of 3.30% compared to the previous year's $56.20 billion. Earnings were $11.84 billion, an increase of 2.55%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $164.94, which is an increase of 19.88% from the latest price.
News
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE...
Should You Pick AbbVie Stock Over LLY?
Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices.
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
NORTH CHICAGO, Ill. , May 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, ...
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
- Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination with methotrexate (MTX), are reported for adult pati...
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health (NYSE:CVS), AbbVie (NYSE:ABBV)
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
US FDA approves Genmab-AbbVie's blood cancer therapy
The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment...
EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NORTH CHICAGO, Ill. , May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only...
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib...
SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval
THE FIRST AND ONLY HYALURONIC ACID INTRADERMAL MICRODROPLET INJECTION, APPROVED FOR IMPROVED SKIN SMOOTHNESS OF THE CHEEKS IRVINE, Calif. , May 15, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an ...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ®) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational us...
Top Ancillary And Medical Marijuana Stocks In May 2023
Are These Cannabis Stocks Good Long-Term Positions? The post Top Ancillary And Medical Marijuana Stocks In May 2023 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Buddi...
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill. , May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023.
Drugmakers brace for serious headwinds ahead
Yahoo Finance's Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching ...
AbbVie stock falls toward a 6-week low after adjusted profit fell short of expectations, but the full-year outlook was raised
Shares of AbbVie Inc. ABBV dove 6.2% toward a six-week low in premarket trading Thursday, after the biopharmaceutical company missed first-quarter profit expectations but lifted its full-year outlook....
AbbVie Reports First-Quarter 2023 Financial Results
Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 ...
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
CHICAGO--(BUSINESS WIRE)---- $ABBV #bigpharma--Consumers sued AbbVie alleging it fraudulently inflated the cost of Humira by 470% over the last two decades, according to attorneys at Hagens Berman.
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional o...
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) f...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
A significantly higher proportion of patients treated with RINVOQ achieved the co-primary endpoints of endoscopic response and clinical remission and the key secondary endpoint of corticosteroid-free ...
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
NORTH CHICAGO, Ill. , April 12, 2023 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF...
Final Trades: Starbucks, Abbvie, Microsoft & APA Corp.
The final trades of the day. With CNBC's Melissa Lee and the Fast Money traders.
Abbvie lowers guidance after $150 million charge
Abbvie Inc. ABBV, +0.64% late Wednesday lowered its guidance for the year to include a charge of about $150 million. The pharma company said GAAP as well as adjusted earnings for its first quarter are...
Final Trades: Abbvie, Thermo Fisher & more
The "Halftime Report" traders give their top picks to watch for the second half.
A Look at Bernard Horn's Top Holdings Ahead of Value Conference
With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in develo...